Hibernia Wealth Partners’s BioLineRX BLRX Stock Holding History

Hibernia Wealth Partners’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-250	Closed	-$2.14K	–	47
2024 Q4	$2.14K	Buy	+250	New	+$3.69K	﹤0.01%	54

Other funds holding BLRX

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

NRG

Nemes Rush Group Novi, Michigan $1.05B AUM 30.08% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Hibernia Wealth Partners's BLRX Position: Q1 2025 in Review

Hibernia Wealth Partners sold out of BioLineRX (BLRX) in Q1 2025, closing a stake of 250 shares — an estimated $2.14K sold.

Hibernia Wealth Partners first reported a position in BLRX in Q4 2024 and held it in 1 quarter. The position peaked at $2.14K in Q4 2024. 12 funds tracked by Wall St. Rank hold BLRX as of Q1 2025.

Hibernia Wealth Partners reported no remaining BioLineRX position as of Q1 2025 after selling out during the quarter.
Hibernia Wealth Partners sold 250 BioLineRX shares in Q1 2025, an estimated $2.14K.
Hibernia Wealth Partners first reported a position in BioLineRX in Q4 2024 and held it in 1 quarter.
Hibernia Wealth Partners's BioLineRX position peaked at $2.14K in Q4 2024.
12 funds tracked by Wall St. Rank held BioLineRX as of Q1 2025.

Based on Hibernia Wealth Partners's 13F filing for Q1 2025, filed 24 Apr 2025.